Acute Myeloid Leukemia

Acute Myeloid Leukemia

Diagnosis and Management of Differentiation Syndrome in Patients With Acute Myeloid Leukemia

Researchers summarize current literature surrounding the diagnosis and management of DS in patients with AML treated with lower-intensity therapies.

Hematology Advisor
Association Analyses of TP53 Mutation With Prognosis, Tumor Mutational Burden, and Immunological Features in Acute Myeloid Leukemia

Somatic mutations in AML patients were found using The Cancer Genome Atlas dataset and BeatAML dataset and then researchers identified the common mutant genes in the two cohorts. 

Frontiers in Immunology
Early Detection of WT1 Measurable Residual Disease Identifies High-Risk Patients Independently of Transplantation in AML

Post-induction WT1 measurable residual disease is associated with shorter survival and higher risk of relapse in younger AML patients.

Blood Advances

Enasidenib Plus Azacitidine versus Azacitidine Alone in Patients With Newly Diagnosed, Mutant-IDH2 Acute Myeloid Leukaemia (AG221-AML-005)

This study evaluated the safety and activity of enasidenib plus azacitidine vs azacitidine alone in patients with newly diagnosed, mutant-IDH2 AML ineligible for intensive chemotherapy.

The Lancet Oncology
Runt-Related Transcription Factor 3 Promotes Acute Myeloid Leukemia Progression

RUNX3 was discovered as an oncogene overexpressed in AML cells, and Runx3 knockdown suppressed AML progression by inducing DNA damage and apoptosis.

Frontiers in Oncology
Higher TOX Genes Expression Is Associated With Poor Overall Survival for Patients With Acute Myeloid Leukemia

Research investigated the expression characteristics and prognostic value of the TOX genes and analyzed the correlation between TOX and IC genes in PB samples from AML patients.

Frontiers in Oncology
The Multi-Omic Prognostic Model of Oxidative Stress-Related Genes in Acute Myeloid Leukemia

This study aims to contribute to the prognosis or monitoring of AML, as well as to clinical therapeutic decision-making, which may provide new evidence for the management of the disease.

Frontiers in Oncology
SIRPα-αCD123 Fusion Antibodies Targeting CD123 in Conjunction with CD47 Blockade Enhance the Clearance of AML-Initiating Cells

This study reports the development of SIRPα-αCD123 fusion antibodies that localize the disruption of CD47/SIRPα signalling to AML while specifically enhancing LSC clearance.

Journal of Hematology & Oncology
MiR-20a-5p Functions As a Potent Tumor Suppressor by Targeting PPP6C in Acute Myeloid Leukemia

This study determined the expression of miR-20a-5p in bone marrow from AML patients and healthy controls and the correlation between miR-20a-5p and clinicopathological variables..

Identification of Seven Novel Ferroptosis-Related Long Non-Coding RNA Signatures as a Diagnostic Biomarker for Acute Myeloid Leukemia

This study aimed to investigate the role of ferroptosis-related long non-coding RNAs (lncRNAs) in AML and establish a corresponding prognostic model.

BMC Medical Genomics
Safety of a Bispecific Antibody in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Investigators aimed to determine the safety and tolerability of APVO436 in patients with R/R AML or MDS and to identify a recommended phase 2 dose (RP2D) level. 

Hematology Advisor
Comprehensive Analysis of Mutations and Clonal Evolution Patterns in a Cohort of Patients with Cytogenetically Normal Acute Myeloid Leukemia

Scientists performed high throughput exome sequencing of matched presentation and relapsed samples from 6 CN-AML patients treated with standard remission induction chemotherapy...

Molecular and Cellular Biology / Genetics
Impact of PTPN11 Mutations on Clinical Outcome Analyzed in 1529 Patients With Acute Myeloid Leukemia

Researchers found a profound new association of the clonal rank of PTPN11 mutations with the comutational spectrum and clinical outcome...

Blood Advances
FDA Grants Fast Track Designation to CRISPR-Edited Stem Cell Therapy for AML

The FDA granted fast track designation to VOR33, an engineered allogeneic stem cell therapy for the treatment of patients with acute myeloid leukemia who are at high risk for relapse.

Nanoparticle T cell Engagers for the Treatment of Acute Myeloid Leukemia

Study investigator findings suggest that nanoTCE technology is a novel and promising immuno-therapy for the treatment of AML.

OncoTargets and Therapy
Researchers Identify a Novel Player in Acute Myeloid Leukemia

A new study has shown the protein RNF5 plays an unusual role in AML. Unlike its expected role, marking aberrant proteins for destruction, RNF5 binds with a second cell protein called...

Nature Communications
Treating AML Patients Ineligible for Intensive Chemotherapy

Dr Keith Pratz details data presented from the Phase III VIALE-A clinical study regarding treatment for AML patients who are ineligible for intensive chemotherapy.

Oncology Times - Latest Articles
Venetoclax Combination Therapy With Hypomethylating Agents in Young Adults With Relapsed/Refractory AML

Investigators summarize the currently available evidence on the treatment of venetoclax in combination with hypomethylating agents for the treatment of young R/R AML patients...

Therapeutic Advances in Hematology
Ficlatuzumab and Chemo in Relapsed/Refractory Acute Myeloid Leukemia

This research study shows signs of clinical efficacy in patients with relapsed/refractory AML when treated with the investigational therapeutic ficlatuzumab, used in combination with CT.

Oncology Times - Latest Articles
PD-1 and TIGIT Are Highly Co-Expressed on CD8+ T Cells in AML Patient Bone Marrow

Study investigators comprehensively compared the distribution of PD-1 and TIGIT in PB and BM T cells from AML patients at the stages of initial diagnosis, complete remission, and R/R disease...

Frontiers in Oncology
Development of Multidrug Resistance in Acute Myeloid Leukemia Is Associated with Alterations of the LPHN1/GAL-9/TIM-3 Signaling Pathway

Here, study investigators prove that latrophilin-1 expression also occurs in the myeloid blasts of patients newly diagnosed with myelodysplastic syndrome when ABCB1 is overexpressed.

Long Non-Coding RNA LINC00152 Regulates Self-Renewal of Leukemia Stem Cells and Induces Chemo-Resistance in Acute Myeloid Leukemia

Herein, the lncRNA, LINC00152, is identified to be highly expressed in CD34+ LSCs and is found to regulate the self-renewal of LSCs derived from AML patients.

Frontiers in Oncology
The Correlation of Next-Generation Sequencing-Based Genotypic Profiles With Clinicopathologic Characteristics in NPM1-Mutated Acute Myeloid Leukemia

The purpose of this study is to analyze the association between NGS genotypic profiles and conventional clinicopathologic characteristics in patients with AML with NPM1 mutation.

BMC Cancer
Association Between Measurable Residual Disease in Patients With Intermediate-Risk AML and First Remission, Treatment, and Outcomes

This study suggests that clinical decisions based on dynamic measurable residual disease might be associated with improved therapy stratification and optimized postremission treatment for patients

JAMA Network
Phase 3 Randomized Trial of Chemotherapy With or Without Oblimersen in Older AML Patients

Oblimersen (G3139) can be safely added to conventional chemotherapy for older patients with AML.

Blood Advances
The Basic Research of the Combinatorial Therapy of ABT-199 and Homoharringtonine on Acute Myeloid Leukemia

Study investigators examine the preclinical efficacy of a new strategy combining ABT-199 with HHT, a selective inhibitor of MCL-1 may be a promising approach for AML treatment...

Frontiers in Oncology
Long Non-Coding RNA LINC00152 Regulates Self-Renewal of Leukemia Stem Cells and Induces Chemo-Resistance in Acute Myeloid Leukemia

In this study, the lncRNA, LINC00152, is identified to be highly expressed in CD34+ LSCs and is found to regulate the self-renewal of LSCs derived from AML patients.

Frontiers in Oncology
Effect of Myeloid Progenitor Cell Product on the Risk of Infection During Induction Chemotherapy for AML

Desai et al find the addition of the myeloid progenitor cell product romyelocel-L to G-CSF reduces the incidence of infection and antimicrobial use vs G-CSF alone during induction CT in AML.

The ASCO Post
DNA-PK Inhibitor Peposertib Enhances p53-Dependent Cytotoxicity of DNA Double-Strand Break Inducing Therapy in Acute Leukemia

Study investigators examine the therapeutic potential of M3814 in combination with DSB-inducing agents in leukemia cells and a patient-derived tumor. 

Scientific Reports
Skin Biopsies in Acute Myeloid Leukemia Patients Undergoing Intensive CT are Safe and Effect Patient Management

The aim of this study was to evaluate the diagnostic yield and safety of skin biopsies obtained from adult patients with AML during hospitalization for intensive chemotherapy.

Scientific Reports
Anti-Tumor Effects of BDH1 in Acute Myeloid Leukemia

In order to find out its role in AML pathogenesis, investigators first analyze the expression levels of 10 key genes involved in ketone metabolism in AML blasts and CD34+ HSCs from healthy donors. 

Frontiers in Oncology
Adrenomedullin Expression Characterizes Leukemia Stem Cells and Associates With an Inflammatory Signature in Acute Myeloid Leukemia

This study shows that ADM expression in AML associates with a stem cell phenotype, inflammatory signatures and genes related to immunosuppression, all factors that contribute to therapy resistance.

Frontiers in Oncology
Chromosomal Instability in Acute Myeloid Leukemia

This review focuses on CIN studies in AML, their prognostic results, as well as the use of CIN as a therapeutic target in AML.


source list reference

rgb(171, 222, 222)
200, 66, 245
rgb(195, 2, 230)
rgb(209, 15, 15)
rgb(115, 43, 196)
rgb(9, 151, 227)
rgb(242, 0, 137)
rgb(48, 38, 189)
rgb(231, 165, 240)
rgb(230, 21, 49)
rgb (252, 186, 3)
rgb(156, 242, 7)
rgb(224, 4, 129)
rgb(80, 147, 199)
rgb(5, 235, 235)
rgb(235, 190, 9)
rgb(209, 227, 11)
200, 66, 245
rgb (132, 101, 173)
rgb(217, 7, 192)
rgb(2, 230, 230)